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Summary
Induction of type I interferons (IFNs) by viruses and
other pathogens is crucial for innate immunity, and
it is mediated by the activation of pattern-recognition
receptors, such as Toll-like receptors and cytosolic re-
ceptors such as RIG-I and MDA5. The type I IFN induc-
tion is primarily controlled at the gene transcriptional
level, wherein a family of transcription factors, inter-
feron regulatory factors (IRFs), plays central roles.
Here, we summarize the recent studies on IRFs, pro-
viding a paradigm of how genes are ingeniously regu-
lated during immune responses. We also consider
some evolutional aspects on the IFN-IRF system.
The IFN Genes: A Brief Overview
IFNs, so called because of their activity to interfere
(inhibit) virus replication in a cell (see Vilcek, 2006, in
this issue), are divided into at least three distinct types:
types I, II, and III (Pestka et al., 2004). Type I IFNs are
composed of various genes including IFN-a, -b (Tanigu-
chi et al., 1980), and others, such as IFN-u, -3, and -k
(Pestka etal., 2004). In humansand mice, the IFN-agenes
are composed of more than 13 subfamily genes (13 in hu-
mans and 14 in mice), whereas only a single IFN-bgene is
found (Weissmann and Weber, 1986); all of these IFN
genes are clustered in one locus on the same chromo-
some (on chromosome 9 in humans and on chromosome
4 in mice).
Type II IFN is referred to as IFN-g, the gene which ex-
ists in a single copy; this gene is structurally unrelated to
type I IFNs and is typically induced in cells of the immune
system such as T cells or natural killer (NK) cells (Farrar
and Schreiber, 1993). Recently, some new IFN gene
members, namely IFN-l1, -l2, and -l3 (also known as
interleukin-29 [IL-29], IL-28A, and IL-28B, respectively)
genes, have been identified and classified as type III
IFN (Pestka et al., 2004). Type III IFN genes are induced
in virally infected cells, and these IFN genes may also be
induced by mechanisms similar to those for IFN-a and
-b genes. The mechanisms of signal transduction by
distinct types of IFNs are described elsewhere (Farrar
and Schreiber, 1993; Pestka et al., 2004; see also van
Boxel-Dezaire et al., 2006 in this issue).
Type I IFN production is primarily controlled at the
gene transcription level; hence, the regulatory mecha-
*Correspondence: tada@m.u-tokyo.ac.jpnism underlying IFN gene transcription has been a focus
of extensive studies even beyond the context of immu-
nity, offering a paradigm on how quiescent genes are
‘‘switched on and off’’ in mammalian cells. In particular,
mechanisms of IFN-b gene induction have been exten-
sively studied over the past few decades. Indeed, as
described below, the IFN-b gene induction occurs as a
highly ordered process, and it is regulated by multiple
transcription factors.
Type I IFN Gene Enhancers and IRFs
The promoter region of the IFN-b gene contains at least
four regulatory cis elements, namely, the positive regu-
latory domains (PRDs) I, II, III, and IV (Figure 1A; Kim
and Maniatis, 1997). In contrast, the promoter regions
of IFN-a genes contain PRD I- and PRD III-like elements
(PRD-LEs) (Ryals et al., 1985). PRD I and PRD III are the
binding sites for IRF family members, whereas PRD II
and PRD IV elements are for nuclear factor-kB (NF-kB)
and AP-1 (a heterodimer of activating transcription
factor 2 [ATF2] with c-JUN), respectively. PRD I is also
bound by PRD I binding factor 1 (PRDI-BF1; known as
Blimp-1 in the mouse), which acts as a negative regula-
tor of IFN-b gene transcription (Gyory et al., 2004). After
viral infections, PRDs direct the assembly of IRFs, NF-
kB, AP-1, and the high-mobility group protein HMG-
I(Y) to form a complex known as the ‘‘enhanceosome’’
(Kim and Maniatis, 1997). The enhanceosome recruits
histone acetyl transferases (HATs), namely, the general-
control-of-amino-acid synthesis 5 (GCN5) and CREB
binding protein (CBP), to acetylate lysine residues of
histones H3 and H4 in the nucleosome (Figure 1B),
which locates at and covers the transcription start site
of the IFN-b gene promoter and inhibits gene induction
in the steady state (Figure 1A; Agalioti et al., 2000).
This histone acetylation then facilitates the recruitment
of a nucleosome modification complex, the Brahma-
related gene (BRG)-Brahma (BRM)-associated factor
(BAF) complex, which forces the nucleosome displace-
ment from the transcription start site (Figure 1C). This
nucleosomal displacement facilitates the recruitment
of the transcription complex TFIID to the promoter
(Figure 1D)—an essential event for the induction of the
IFN-b gene expression (Agalioti et al., 2000).
Notably, the IFN-b promoter is activated only weakly,
if at all, by tumor necrosis factor-a (TNF-a), which leads
to activation of NF-kB and AP-1, but not IRFs (Reis et al.,
1989). Interestingly, however, if the nucleosome on the
transcription start site is artificially displaced, an event
resembling viral infections, the IFN-b gene promoter is
now efficiently activated after TNF-a stimulation (Lom-
vardas and Thanos, 2002). These observations together
support the view that the alteration of the nucleosome
structure is a critical determinant in balancing the mag-
nitude of IFN-b induction and that a robust IFN-b induc-
tion for antiviral immune responses is contingent on the
involvement of activated IRFs, without which a recruit-
ment program for chromatin modifiers and the tran-
scriptional basal machinery to the promoter cannot be
initiated.
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The IRF family of transcription factors comprises nine
members: IRF1, IRF2, IRF3, IRF4 (also known as PIP
or ICSAT), IRF5, IRF6, IRF7, IRF8 (also known as ICSBP),
and IRF9 (also known as ISGF3g) (Mamane et al., 1999;
Taniguchi et al., 2001). These family members are char-
acterized by a well-conserved amino (N)-terminal DNA
binding domain (DBD) with five tryptophan repeats,
bearing resemblance to the DBD of myb transcription
factors (Taniguchi et al., 2001; Veals et al., 1992). The
DBD forms a helix-turn-helix domain and recognizes
similar DNA sequences. An analysis of the crystal struc-
ture of a DBD of IRF1 bound to the PRD I of the IFN-b en-
hancer revealed that 50-GAAA-30 is the recognition se-
quence of the helix-turn-helix motif of IRF1 (Escalante
et al., 1998). Subsequently, an analysis of the crystal
structure of a DBD of IRF2 complexed with a tandem re-
peat of GAAA revealed that 50-AANNGAAA-30 is the con-
sensus IRF recognition sequence (Fujii et al., 1999). The
Figure 1. IFN-b Gene Transcription after Viral Infection
(A) In the steady state, the transcription start site (located at +1 base
pairs, bp) of the IFN-b gene is covered by a positioned nucleosome.
(B) After viral infection, PRD I-IV direct the assembly of ATF2 and
c-JUN, IRFs, NF-kB, and HMG-I(Y)—a complex known as the enhan-
ceosome. The enhanceosome recruits HATs, such as GCN5 and
CBP/p300, which acetylate (Ac) a subset of lysine residues of his-
tones in the nucleosome.
(C) Next, the RNA polymerase II holoenzyme (lacking the transcrip-
tion factor TFIID) is recruited to the promoter. The chromatin-remod-
eling complexes such as BAF complexes are then recruited, by
contacting the acetylated histone.
(D) BAF complexes induce nucleosome displacement from the tran-
scription start site, making it accessible to TFIID for the induction of
IFN-b expression.50 flanking AA sequence is essential for the recognition
by IRFs and, therefore, IRFs do not bind to the NF-kB
binding site, which contains the GAAA core sequence
but no 50 flanking AA sequence. It was also shown that
the interaction of an IRF DBD with the core motif
GAAA results in DNA structure distortion, which may al-
low the cooperative binding of another IRF DBD to the
IRF binding site that usually contains dimeric repeats
of the core sequence (Fujii et al., 1999). On the basis of
this model, it can also be assumed that such a DNA dis-
tortion mechanism underlies a cooperative interaction
of IRFs with other transcriptional factors, such as AP-1
or NF-kB, at the IFN-b enhancer, so as to contribute to
the above-mentioned assembly of the IFN-b enhanceo-
some and an efficient transcriptional activation.
The carboxy (C)-terminal regions of IRFs, except IRF1
and IRF2, have an IRF association domain (IAD) that is
responsible for homo- and heteromeric interactions
with other family members or transcription factors such
as PU.1 and signal transducer and activator of transcrip-
tion (STAT) (Mamane et al., 1999; Taniguchi et al., 2001).
Despite the low sequence similarity, the IADs show
structural similarities with the Mad-homology 2 (MH2)
domains of the Smad family of transcription factors,
which mediate protein-protein interaction (Qin et al.,
2003; Takahasi et al., 2003). Indeed, the interaction and
cooperation of IRF7 with Smad3 for the activation of
type I IFN gene transcription has been shown (Qing
et al., 2004). Gene-disruption studies of most of the
genes that encode IRFs have been carried out, show-
ing that IRFs have distinct roles in the development
and function of immune cells, and these studies are
described elsewhere (Honda and Taniguchi, 2006; Loh-
off and Mak, 2005; Taniguchi et al., 2001).
Among IRFs, four IRFs—IRF1, IRF3, IRF5, and IRF7—
have been implicated as positive regulators of type I IFN
gene transcription. IRF1 is the first family member dis-
covered to activate type I IFN gene promoters (Miya-
moto et al., 1988). The overexpression of IRF1 results
in the induction of endogenous type I IFN genes. Al-
though IRF1 participates in type I IFN gene induction
in some facets of TLR signaling (described in a later sec-
tion), the induction of type I IFN was normally observed
in virus-infected Irf12/2 fibroblasts (Matsuyama et al.,
1993). Gene-targeting study also revealed that IRF5 is
dispensable for type I IFN gene induction by viruses or
TLR agonists but, instead, IRF5 regulates the expres-
sion of inflammatory cytokine genes, such as interleukin
(IL)-12 and TNF-a (Takaoka et al., 2005). Hence, the pre-
cise role of IRF1 and IRF5 in type I IFN induction still
remains unclear.
IRF3 and IRF7
IRF3 and IRF7, which are highly homologous, have
gained much attention as the key regulators of type I
IFN gene expression induced by viruses. IRF3 is consti-
tutively expressed and resides in the cytosol in the latent
form. It undergoes phosphorylation, dimerization, and
nuclear translocation upon viral infection (Lin et al.,
1998; Sato et al., 1998a; Yoneyama et al., 1998). IRF3
has potential virus-mediated phosphorylation sites in
the C-terminal region (serine 385, 386 [‘‘2 S site’’] and
serine 396, 398, 402, 405, and threonine 404 [‘‘5 ST
site’’] of human IRF3). The phosphorylation of serine
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cific antibody (Servant et al., 2003). Another report dem-
onstrated that the phosphorylation of serine 386 is the
critical determinant for the activation of IRF3 (Mori
et al., 2004). No direct evidence for the phosphorylation
of the remaining five serine or threonine sites has been
reported. On the basis of the crystal structure of IRF3,
two models of IRF3 activation and dimerization are pro-
posed. One is the ‘‘phosphorylation-induced dimeriza-
tion model,’’ in which the phosphorylated serine resi-
dues of the 2 S site of IRF3 tend to interact with a
hydrophobic pocket within the IAD of another IRF3 or
presumably that of IRF7, resulting in the homo- or heter-
odimerization (Takahasi et al., 2003). Notably, the 2 S
site in C terminus and hydrophobic pocket in IAD are
both highly conserved between IRF3 and IRF7. The
other model is the ‘‘autoinhibitory model,’’ in which N-
and C-terminala-helical structures flanking ab sandwich
IAD core interact to form a condensed hydrophobic
structure in the inactive state: this structure is opened
by the introduction of massive negative charges after
the multiple phosphorylation of C-terminal serine or
threonine residues including the 2 S and 5 ST sites, re-
sulting in IRF3 activation and dimerization (Qin et al.,
2003). Whatever the mechanism, the dimeric form of
IRF3 (either a homodimer or a heterodimer with IRF7)
then translocates to the nucleus, forms a complex with
the coactivators CBP and/or p300, and binds to its tar-
get DNA sequence in type I IFN genes as well as certain
cytokine and chemokine genes to alter the local chro-
matin structure and switch on the gene as described
above (Lin et al., 1998; Sato et al., 1998a; Yoneyama
et al., 1998).
Unlike IRF3, IRF7 is expressed at a low amount in
most cells and is strongly induced by type I IFN-medi-
ated signaling (Marie et al., 1998; Sato et al., 1998b).
That is, the binding of IFNs to the type I IFN receptor re-
sults in the activation of a hetero-trimeric transcriptional
activator, termed IFN-stimulated gene factor 3 (ISGF3),
which consists of IRF9, STAT1, and STAT2, and is re-
sponsible for the induction of the IRF7 gene. Similar to
IRF3, IRF7 resides in the cytosol and, on viral infection,
undergoes serine phosphorylation in its C-terminal re-
gion, allowing its dimerization and nuclear translocation.
IRF7 forms a homodimer or a heterodimer with IRF3,
and each of these different dimers differentially acts on
the type I IFN gene family members. IRF3 is more potent
in activating the IFN-b gene than the IFN-a genes,
whereas IRF7 efficiently activates both IFN-a and IFN-
b genes (Marie et al., 1998; Sato et al., 1998b). It is inter-
esting to note that IRF7 has a very short half-life (w0.5–1
hr) (Sato et al., 2000), owing to its susceptibility to ubiq-
uitin-dependent degradation (Yu et al., 2005), so this la-
bile nature of IRF7 may represent a mechanism critical
to rendering the entire IFN gene-induction process tran-
sient to prevent the overexpression of IFNs that may be
harmful to the host.
The cellular events controlling the activity of IRF3 and
IRF7 have been elucidated in recent years; they consti-
tute crucial antiviral pathways that are triggered by the
detection of molecular patterns derived from viruses.
There are at least two PRR systems in place that detect
the presence of virus: that is, transmembrane PRRs,
namely, TLRs; and cytosolic PRRs, which include reti-noic acid-inducible gene I (RIG-I) and melanoma differ-
entiation-associated gene 5 (MDA5). In the following
sections, we discuss the signaling cascades evoked
by two distinct receptors for type I IFN gene induction
and the distinct contributions of IRFs to these pathways.
Type I IFN Gene Induction by Cytosolic Pathways:
RIG-I and MDA5 Signaling
Before the identification of the TLR system, the studies
of the transcriptional regulation of IFNs were mainly car-
ried out with fibroblasts infected by viruses. Most RNA
viruses, for example, Newcastle disease virus (NDV; a
negative-sense single-stranded [ss] RNA virus), vesicu-
lar stomatitis virus (VSV; a negative-sense ssRNA virus),
and encephalomyocarditis virus (EMCV; a positive-
sense ssRNA virus), have long been known to elicit the
production of type I IFNs in fibroblasts. This classically
known pathway for type I IFN gene induction has re-
cently been revealed to be activated mainly by TLR-in-
dependent cytosolic recognition systems, mediated
by RNA-sensing molecules such as RIG-I and MDA5.
Thus, this pathway can be referred to as the ‘‘cytosolic
pathway,’’ in contrast to the recently discovered TLR
pathway of type I IFN gene induction (discussed later).
The cytosolic pathway leading to type I IFN gene in-
duction is initiated by the recognition of intracellular
virus-associated molecular patterns. The best-charac-
terized molecular pattern is double-stranded (ds) RNA,
a pathogen-associated molecular pattern (PAMP) that
is produced by many viruses during their replication cy-
cle. The first identified sensor of intracellular dsRNA is
PKR, whose catalytic activity is stimulated by its binding
to dsRNA. However, although PKR contributes to type I
IFN production in response to the synthetic dsRNA ana-
log poly(I:C), gene targeting in mice has shown that it is
superfluous for IFN responses to viral infection (Yang
et al., 1995). Recently, RIG-I and MDA5 have been iden-
tified as essential cytosolic receptors for intracellular
viral RNAs and synthetic dsRNAs, mediating the TLR-
independent induction of type I IFN genes (Yoneyama
et al., 2004, 2005).
RIG-I and MDA5 contain a C-terminal DExD/H box
RNA helicase domain as well as two N-terminal cas-
pase-recruitment and activation domains (CARDs) (Fig-
ure 2). The DExD/H box is a characteristic amino acid
signature motif of many RNA binding proteins. The inter-
actions of DExD/H box RNA helicase domains with viral
RNA or synthetic dsRNA induce the unwinding of RNAs
by means of energy derived from ATP hydrolysis and, at
the same time, induce conformational changes of RIG-I
and MDA5 to promote the CARD-mediated downstream
signaling cascades, leading to the activation of IRF3,
IRF7, and NF-kB for the induction of type I IFN genes
and proinflammatory cytokines, such as IL-6. RIG-I
and MDA5 are inducible by type I IFN stimulation and
are therefore involved in the positive feedback regula-
tion of type I IFN signaling (Kang et al., 2002). Definitive
evidence for the essential role of RIG-I and MDA5 in re-
sponses to RNA viruses has been obtained by generat-
ing mice deficient in the RIG-I or MDA5 gene (Kato et al.,
2005, 2006). RIG-I-deficient mice are defective for the
induction of type I IFN and proinflammatory cytokines
in response to infections by negative-sense ssRNA vi-
ruses, such as NDV, VSV, Influenza virus, and Sendai
Immunity
352Figure 2. IRF Activation by Cytosolic Pattern-Recognition Systems; Operation of a Positive-Feedback Mechanism
The presence of dsRNA in the cytosol triggers host responses via a specific cytosolic pattern-recognition system. The interaction of dsRNA—
a replication intermediate of positive (+) and negative (2) RNA viruses—with the helicase domain of RIG-I and MDA5 induces the unwinding of
dsRNA and, at the same time, induces the conformational change of RIG-I and MDA5. The conformational change promotes the interaction be-
tween the RIG-I and MDA5 CARDs and the CARD-containing adaptor protein IPS-1, which is located on the mitochondrial membrane, resulting in
the activation of TBK1 via TRAF3 as well as IKK complex via FADD, RIP1 (not depicted), and TRAF6. Activated TBK1 induces the phosphorylation
(P2) of IRF3 and IRF7, resulting in their homo- or heterodimerization. These dimers then translocate to the nucleus and induce chemokines (in-
cluding CXCL10) as well as small amounts of IFN-b. Secreted IFN-b then stimulates type I IFN receptor (heterodimer of IFNAR1 and IFNAR2) in
an autocrine and a paracrine fashion, leading to activation of ISGF3 (heterotrimer of STAT1, STAT2, and IRF9) and the transcription of IRF7 gene.
Activation of the newly synthesized IRF7 results in further amplification of transcription for IFN-b and many of the IFN-a genes, and thereby a
positive-feedback loop is operational.virus (SeV), as well as positive-sense ssRNA viruses,
such as Japanese encephalitis virus. In contrast, MDA5-
deficient mice show defects in their responses to infec-
tions by positive-sense ssRNA viruses, such as EMCV,
Theiler’s virus, and Mengo virus. Thus, RIG-I and
MDA5 cooperate to ensure effective innate antiviral re-
sponses to negative- and positive-sense ssRNA viruses.
In addition to RIG-I and MDA5, another DExD/H box
RNA helicase—Lgp2—has been identified (Yoneyama
et al., 2005). Lgp2 contains a DExD/H box RNA helicase
domain but lacks CARDs or any other signaling do-
mains, so it might negatively regulate the RIG-I and
MDA5 signaling pathways by competing with these
molecules for engagement with viral RNAs.
The Downstream Adaptor
The adaptor molecule that connects the sensing of in-
coming viral RNA by RIG-I or MDA5 to downstreamsignaling and gene activation has been identified to
be a molecule with multiple nomenclatures, namely,
IFN-b promoter stimulator 1 (IPS-1) (Kawai et al., 2005),
mitochondrial antiviral signaling (MAVS) (Seth et al.,
2005), CARD adaptor inducing IFN- b (Cardif) (Meylan
et al., 2005), and virus-induced signaling adaptor
(VISA) (Xu et al., 2005). (We will refer to this molecule
as IPS-1 in this review, but acknowledge that currently
there is no consensus on naming it.) IPS-1 has an N-ter-
minal CARD that shares homology with those of RIG-I
and MDA5. This CARD mediates CARD-CARD interac-
tions with RIG-I and MDA5 and transmits downstream
signaling (Figure 2). IPS-1 also contains a C-terminal hy-
drophobic transmembrane (TM) region, which resem-
bles that of several mitochondrial proteins, including
apoptotic regulators of the BCL-2 family, and indeed
mediates the localization of IPS-1 in the outer mitochon-
drial membrane (Seth et al., 2005). Mutation studies
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tial for the function of IPS-1.
Definitive evidence for the essential role of IPS-1 in
RIG-I- and MDA5-mediated signaling for type I IFN, in-
flammatory cytokine, and chemokine gene induction
has been obtained by generating mice deficient in this
gene (Kumar et al., 2006; Sun et al., 2006). IPS-1 has
been shown to interact with several signaling proteins,
such as tumor necrosis factor receptor-associated fac-
tor 2 (TRAF2), TRAF6, Fas-associated protein with the
death domain (FADD), and receptor interacting pro-
tein-1 (RIP1) (Kawai et al., 2005; Xu et al., 2005). These
molecules presumably participate in NF-kB activation
and proinflammatory cytokine induction. IPS-1 also in-
teracts with TRAF3, which is required for the activation
of kinases for IRFs (described below) to induce type I
IFN gene induction (Figure 2; Oganesyan et al., 2006;
Saha et al., 2006).
The TBK1 and IKKi Kinases
TANK binding kinase 1 (TBK1; also known as T2K and
NAK), which was originally identified in the context of
the regulation of NF-kB activity, is the essential serine-
threonine kinase for the phosphorylation of IRF3 and
IRF7 (Figure 2; Fitzgerald et al., 2003; Sharma et al.,
2003; Hemmi et al., 2004). Although TBK1 is not associ-
ated with IPS-1 as determined by immunoprecipitation
assay (Kawai et al., 2005; Meylan et al., 2005), TBK1
must be activated downstream of this adaptor. It is inter-
esting to note that embryonic fibroblasts (MEFs) from
Traf32/2 mice are deficient in type I IFN gene induction
by VSV (Oganesyan et al., 2006). Considering the fact
that TRAF3 interacts with IPS-1 (Saha et al., 2006),
TRAF3 probably provides a link between IPS-1 and
TBK1 (Figure 2). Inducible IkB kinase (IKKi; also known
as IKK3), which is structurally related to TBK1, was
also shown to phosphorylate IRF3 and IRF7 in vitro;
however, gene-targeting studies revealed that the con-
tribution of IKKi to the cytosolic pathway is minor
(Hemmi et al., 2004).
Contributions of IRF3 and IRF7
to the Cytosolic Pathway
The induction of IFN-a and IFN-b mRNAs by NDV was
found to be normal in Irf12/2 (Matsuyama et al., 1993)
as well as Irf52/2 MEFs (T.T., unpublished observation),
indicating that neither IRF1 nor IRF5 is essential for the
cytosolic pathway. IRF3 and IRF7 are now known to
be essential for the RIG-I- and/or MDA5-mediated type
I IFN gene-induction pathway. Initial experimental stud-
ies seemed to favor the hypothesis that IRF3 is primarily
responsible for the initiation of IFN-b induction, whereas
IRF7, which is induced by IFN-b, comes into play in the
later phase for IFN-a induction (‘‘two-step’’ model). In-
deed, Irf32/2 mice are vulnerable to EMCV infection,
and type I IFN mRNA expression induced by NDV is
markedly impaired in Irf32/2 MEFs (Sato et al., 2000).
Furthermore, IFN-a gene induction is affected in MEFs
from mice deficient in IFN-b gene (Erlandsson et al.,
1998). However, a subsequent gene-targeting study of
IRF7 revealed that, without IRF7, both early and later
phases of type I IFN gene induction by viruses are abol-
ished (Honda et al., 2005b). Although type I IFN gene in-
duction occurs as a sequential event and the positive-feedback regulation via IFN-mediated IRF7 induction
must be operational in the later phase, IRF7 plays a piv-
otal role in the early and late phases of type I IFN gene
induction, and the contribution of IRF3 is minor in the ab-
sence of IRF7 (Figure 2). That is, the homodimer of IRF7
or the heterodimer of IRF7 and IRF3, rather than the IRF3
homodimer, may be more critical for the cytosolic path-
way of type I IFN gene induction (Figure 2). It is likely that
the IRF3 homodimer participates in the induction of
other genes such as chemokine genes (Figure 2).
Viral Factors Affecting IRF-IFN Pathway
Many viruses have, in turn, evolved efficient means of
subverting host immune responses by interfering with
IRF3 and IRF7 activities. Some viruses produce a protein
that directly binds to and prevents the transactivation
ability of IRF3 or IRF7, including the E6 oncoprotein of
the human papillomavirus (Ronco et al., 1998), the
NSP1 of the rotavirus (Graff et al., 2002), and the RTA
protein of Kaposi’s sarcoma-associated herpesvirus
(Yu et al., 2005). In addition, other viruses produce pro-
teins that can interact with CBP/p300 and alter their in-
teraction with IRFs, such as the vIRF-1 protein of human
herpesvirus 8 (Lin et al., 2001). Interestingly, it has been
shown that hepatitis C virus (HCV) nonstructural pro-
teins 3 and 4A (NS3/4A) cleave IPS-1, thereby inhibiting
the RIG-I- and MDA5-mediated activation of IRF3 and/or
IRF7 during HCV infection (Meylan et al., 2005). The
cleavage occurs at a cysteine residue near the C-termi-
nal transmembrane region, resulting in the inactivation
of IPS-1 caused by its release from the mitochondria
(Seth et al., 2005). These observations further under-
score the importance of the RIG-I- or MDA5-IPS-1-IRF
pathway in immunity against viral infections and sug-
gest an interesting association among viral infection, mi-
tochondrial function, and innate immunity development.
IRFs in Other Intracellular Pathways
Similar to viruses, intracellular bacteria, such as Listeria
monocytogenes, have a cytosolic phase in their life cy-
cle. The cytosolic recognition of L. monocytogenes re-
sults in IFN-b gene induction through the TBK1-IRF3
pathway, as shown by the absence of IFN-b production
in macrophages from Tbk12/2 or Irf32/2 mice (Stock-
inger et al., 2004). Furthermore, a mutant bacterium
lacking listeriolysin O (LLO), which is required for the es-
cape of L. monocytogenes from phagosomes into the
cytosol, does not induce IFN-b gene expression (Stock-
inger et al., 2004). More recently, it has been shown that
L. monocytogenes extracts that were pretreated with
DNase had an impaired ability to induce IFN-b produc-
tion, indicating a role of bacterial DNA present in the cy-
tosol in the IFN-b gene induction (Stetson and Medzhi-
tov, 2006a). Furthermore, the transfection of cells with
dsDNA derived from either a pathogen or the host has
been shown to induce type I IFN genes, as well as
many IFN-inducible genes, via a TLR-independent path-
way (Ishii et al., 2006; Stetson and Medzhitov, 2006a).
This type I IFN gene induction pathway requires TBK1,
as well as IRF3 (the role of IRF7 has not been assessed
yet). It has also been shown that the optimal stimulatory
activity of dsDNA is dependent on the DNA having the
right-handed B-form helical structure, because Z-form
DNA demonstrates a very low activity, suggesting that
Immunity
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structure (Ishii et al., 2006). Taken together, these results
provide evidence of a unique pathway for the recogni-
tion of cytosolic DNA that results in the activation of
IRF3 by as yet unidentified receptor(s) (see also the
accompanying review by Stetson and Medzhitov, 2006b).
It has been shown that some IRFs also function in re-
sponse to stress, such as DNA damage. IRF1 is the first
example, and it is stabilized in cells exposed to DNA-
damaging agents to induce the gene that encodes
p21WAF1/Cip1 (Tanaka et al., 1996). It has also been re-
ported that IRF3 and IRF7 undergo phosphorylation,
mediated by DNA-dependent protein kinase (DNA-PK),
and nuclear translocation in response to genotoxic
stress (Karpova et al., 2002; Kim et al., 2000). It may be
an interesting future issue whether or how stress-in-
duced IRF activation participates in type I IFN response.
IRFs in Induction of Type I IFN Genes by TLRs
The TLR family consists of germline-encoded trans-
membrane receptors in mammals (10 genes in humans
and 12 in mice). Each TLR recognizes various PAMPs
derived from bacteria, viruses, fungi, and/or protozoa
(Akira et al., 2006; Janeway and Medzhitov, 2002). All
TLRs contain intracellular Toll-IL-1 receptor (TIR) do-
mains, which transmit downstream signals via the re-
cruitment of TIR-containing adaptor proteins, such as
myeloid differentiation primary response gene 88
(MyD88), the TIR domain-containing adaptor protein (TI-
RAP; also called MAL), the TIR domain containing adap-
tor-inducing IFN (Trif; also called TICAM1), and the Trif-
related adaptor molecule (TRAM; also called TICAM2)
(Akira et al., 2006; Seya et al., 2005). Signaling through
TLRs can be broadly categorized into two pathways:
the MyD88-dependent pathway and the Trif-dependent
pathway. All TLRs, except TLR3, activate the MyD88-de-
pendent pathway, whereas only TLR3 and TLR4 activate
the Trif-dependent pathway. Both pathways are linked
to the activation of two major downstream pathways:
the NF-kB pathway and the mitogen-activated protein
kinase (MAPK) pathway. In addition, there is accumulat-
ing evidence that IRFs are also activated by the MyD88-
dependent and/or Trif-dependent signaling pathways
and contribute to type I IFN gene expression.
Trif Signaling Pathway for IRF3 Activation
TLR4 is the only receptor that can induce type I IFN (IFN-
b, not IFN-a) gene by recognizing nonnucleic acid li-
gands, such as lipopolysaccharide (LPS). TLR4 is ex-
pressed on the plasma membrane, and the extracellular
portion of TLR4 associates with MD-2, which is prereq-
uisite for TLR4 oligomerization and downstream signal-
ing upon the recognition of LPS (Shimazu et al., 1999).
The TLR4-MD-2 complex requires the aid of CD14,
a high-affinity receptor for LPS, for the recognition of
LPS and subsequent activation of the IFN-b induction
pathway (Figure 3A; Jiang et al., 2005).
The receptor complex composed of CD14, TLR4, and
MD-2 stimulates the signaling pathway through the
adaptor proteins TRAM and Trif, which leads to the
activation of TBK1 (Hemmi et al., 2004; Hoebe et al.,
2003; Yamamoto et al., 2003). The activated TBK1 medi-
ates phosphorylation of serine residues in IRF3, ratherthan those in IRF7, inducing its dimerization and entry
into the nucleus where it induces the transcription of
the IFN-b gene. Indeed, the induction of IFN-b in re-
sponse to LPS is abolished in Irf32/2 dendritic cells
(DCs) (Sakaguchi et al., 2003), whereas it is almost nor-
mal in Irf72/2 cells (Honda et al., 2005b). In addition,
Irf32/2 cells show a defect in the induction of other
genes, such as those that encode CXC-chemokine li-
gand 10 (CXCL10) and CXCL9 (Sakaguchi et al., 2003).
Therefore, the induction of IFN-b and chemokines by
TLR4 is mediated by an IRF3 homodimer via the phos-
phorylation of IRF3 by TBK1. It is not known why
TLR4-mediated activation of TBK1 via Trif is linked to
activation of IRF3, but not IRF7, in contrast to IPS-1-me-
diated activation of TBK1, which efficiently activates
IRF7 (Honda et al., 2005b; Sakaguchi et al., 2003).
TLR3 recognizes poly(I:C) and probably viral dsRNAs
derived from dsRNA viruses such as reovirus, or ssRNA
viruses such as West Nile virus, respiratory syncytial vi-
rus, and EMCV (Alexopoulou et al., 2001; Schulz et al.,
2005; Wang et al., 2004). With some exceptions (i.e.,
cell-surface expression by epithelial cells or NK cells),
TLR3 is expressed in endosomes and phagosomes
and requires the acidification of these vesicles for its sig-
naling (Matsumoto et al., 2003). Indeed, in DCs, TLR3
acts as a key factor for sensing the presence of a viral in-
fection in phagocytosed dying cells (Schulz et al., 2005).
Furthermore, it was shown that TLR3 physically interacts
with CD14, which binds dsRNA and facilitates the uptake
of dsRNA into endosomes (Lee et al., 2006). Crystallo-
graphic studies have shown that TLR3 directly binds to
dsRNA and forms a dimer to activate downstream sig-
naling (Choe et al., 2005). In a similar way to the TLR4 sig-
naling, TLR3 activates the Trif- (TRAM is not involved),
TBK1-, and IRF3-dependent pathway to induce IFN-
b gene (Figure 3B). Indeed, the induction of IFN-b gene
by poly(I:C) is severely impaired in Trif2/2, Tbk12/2, or
Irf32/2cells (Hemmi et al., 2004; Hoebe et al., 2003; Saka-
guchi et al., 2003). The recognition of dsRNA by TLR3 re-
sults in the phosphorylation of two specific tyrosines
(Tyr759 and Tyr858) within the cytoplasmic tail of TLR3
and the recruitment of phosphatidylinositol 3-kinase
(PI3K) to the receptor (Sarkar et al., 2004). Without the
activity of PI3K, IRF3 is incompletely phosphorylated,
suggesting that PI3K activity might be required for the
full activation of IRF3 in TLR3 signaling. It was also
reported that the tyrosine kinase c-Src is activated by
poly(I:C), associates with TLR3, and is essential for
dsRNA-induced IRF3 activation (Johnsen et al., 2006).
However, the precise role of c-Src remains to be clarified.
Several molecules have been shown to interact with
Trif and have been implicated in linking Trif with the sub-
sequent TBK1 and IRF3 activation. It was first shown that
TRAF6 interacts with the N-terminal region of Trif
through its TRAF domain (Sato et al., 2003). However,
a study with Traf62/2 mice indicates that TRAF6 is dis-
pensable for signaling via the Trif-dependent pathways
of TLR3 and TLR4 (Gohda et al., 2004). TRAF1 and
TRAF4 have also been implicated in the Trif-dependent
IFN induction pathway; in this case, however, they
were found to be negative regulators (Su et al., 2006;
Takeshita et al., 2005). RIP1 interacts with Trif through
the C-terminal RIP homotypic interaction motif (RHIM) of
Trif (Meylan et al., 2004). Although RIP1 was found to be
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355Figure 3. TLR-Mediated Type I IFN Induction Pathways
(A) The receptor complex composed of TLR4, MD-2, and CD14 recognizes LPS and signals through at least four adaptors: TIRAP, MyD88, TRAM,
and Trif. Among them, TRAM and Trif mediate the activation of IRF3. Trif associates with TBK1 through TRAF3 and NAP1, which mediates the
phosphorylation of IRF3. Phosphorylated IRF3 forms homodimers and induces IFN-b and Cxcl10 genes.
(B) TLR3 (expressed in endosomes) activates IRF3 through a pathway similar to that utilized by TLR4. PI3K is recruited to the phosphorylated
tyrosine residues of TLR3 and supports the activation of IRF3. The tyrosine kinase c-Src also associates with TLR3 and is involved in the
activation of IRF3; however, the precise role of c-Src remains to be clarified.
(C) Upon TLR7 or TLR9 (expressed in endosomes) stimulation, IRF7 interacting with MyD88 is activated by the IRAK4-IRAK1-IKKa kinase cas-
cade. The exact function of the other molecules depicted here is not known. Secreted type I IFNs enhance the expression of IRF7 gene, leading to
further enhancement of type I IFN gene induction.
(D) IFN-g stimulation induces the expression of IRF1 via the formation of homodimers of STAT1. Induced IRF1 interacts with and is activated by
MyD88 by an as yet unknown mechanism and translocates to the nucleus to induce IFN-b, iNOS, and IL-12p35 genes. Note that all pathways
depicted here operate in a cell type-specific manner.an essential mediator of the activation of NF-kB, IFN-b
induction occurs normally in RIP1-deficient cells upon
TLR3 activation (Meylan et al., 2004). Recently, TRAF3
has shown to interact with Trif, as well as TBK1, and
positively regulate Trif-dependent IFN-b induction (Oga-
nesyan et al., 2006). It has also been reported that the
NAK-associated protein 1 (NAP1) associates with Trif
and is required for inducing the oligomerization and acti-
vation of TBK1 (Sasai et al., 2005). These reports collec-
tively indicate that TRAF3 and NAP1 interact with Trif and
cooperate with each other to activate TBK1 and IRF3.
MyD88 Signaling Pathway for IRF7 Activation
Much attention has been focused on the high induction
of type I IFN genes in plasmacytoid DCs (pDCs) (Fig-
ure 3C; Colonna et al., 2004). In contrast to conventional
DCs and MEFs, pDCs use the TLR system—in particular,
members of the TLR9 subfamily of TLRs (that is, TLR7
and TLR9), which are expressed in endosomes—instead
of RIG-I or MDA5 to detect viruses (Akira et al., 2006).
DNA viruses such as herpes simplex virus (HSV) contain
many unmethylated CpG motifs in their genome, which
are recognized by TLR9 and induce robust type I IFN
production in pDCs (Krug et al., 2004; Lund et al.,2003). Likewise, TLR7 signaling is essential for type I
IFN induction in response to influenza virus or VSV infec-
tion by recognizing viral genomic ssRNA (Diebold et al.,
2004; Heil et al., 2004). In contrast to TLR3- or TLR4-
mediated Trif-dependent IFN gene induction, the TLR9
subfamily members exclusively utilize MyD88 as the
signaling adaptor.
MyD88 directly interacts with IRF7 (not with IRF3)
through its death domain (Figure 3C; Honda et al.,
2004; Kawai et al., 2004). Splenic pDCs derived from
Irf72/2 mice exhibit a profound defect in type I IFN
gene induction either by viral infections (HSV and VSV)
or synthetic TLR ligands, whereas the induction is nor-
mal in Irf32/2 pDCs (Honda et al., 2005b). Therefore, in
contrast to the IRF3-dependent IFN-b gene induction
by the Trif pathway, the MyD88-dependent robust IFN
gene induction in pDCs is absolutely dependent on
IRF7 (Figure 3C).
IRF7 also interacts with TRAF6, another adaptor mol-
ecule functioning downstream of MyD88, and the over-
expression of TRAF6 induces type I IFN genes through
the activation of IRF7 (Honda et al., 2004; Kawai et al.,
2004). Furthermore, pDCs derived from Irak42/2 or
Irak12/2 mice have a defect in IFN-a production
Immunity
356activated by the TLR9 subfamily (Honda et al., 2004; Ue-
matsu et al., 2005). In view of the recent report demon-
strating that IKKa is also essential for the phosphoryla-
tion of IRF7 (Hoshino et al., 2006), it is likely that the
IRAK4-IRAK1-IKKa kinase cascade, known to be opera-
tional in the NF-kB activation pathway, leads to IRF7 ac-
tivation (Figure 3C). TRAF3 and osteopontin (Opn) have
also been shown to be integral members of this pathway
(Oganesyan et al., 2006; Shinohara et al., 2006); how-
ever, their exact functions are still unknown.
Spatiotemporal Regulation of MyD88-IRF7
Pathway in pDCs
Although the essential role of IRF7 in MyD88-dependent
IFN gene induction is clear, another interesting, unan-
swered question is why pDCs—but not other cell types,
such as conventional DCs—produce large amounts of
type I IFNs. Although it was assumed that a higher con-
stitutive expression of IRF7 in pDCs than in conventional
DCs may be responsible (Colonna et al., 2004), this does
not fully account for the robust type I IFN gene induction.
Instead, a mechanism that probably accounts for the
specific ability of pDCs to produce type I IFN is the spa-
tiotemporal regulation of TLR7 and TLR9 signaling.
The TLR9 ligand A- or D-type CpG-DNA (CpG-A) (Klin-
man, 2004), which induces a robust IFN-a production by
pDCs, localizes for a long period in the endosomal com-
partment in pDCs, whereas it is not retained in endo-
somes but ends up in lysosomes in conventional DCs
or macrophages (Honda et al., 2005a). Even in pDCs,
B- or K-type CpG-DNA (CpG-B) (Krieg, 2002) is quickly
transported into lysosomes and does not induce IFN-
a production. Therefore, the endosomal retention of
ligands in pDCs probably provides a platform for inter-
actions between MyD88 and IRF7. Indeed, artificially
manipulating the transport of CpG-A to endosomes by
mixing with cationic lipids resulted in the colocalization
of CpG-A with MyD88 and IRF7, which in turn resulted in
a high IFN-a production in conventional DCs and macro-
phages (Honda et al., 2005a). Similar observations have
been made with human pDCs (Guiducci et al., 2006).
Thus, pDCs seem to have a unique mechanism of retain-
ing CpG-A in endosomes, and a prolonged signaling
may allow the phosphorylation of de novo synthesized
IRF7 and the continuous activation of the positive-feed-
back system to induce a robust type I IFN production
(Figure 3C). It has been shown that viruses such as
VSV and HSV tend to reside in endosomes after infection
(Brunetti et al., 1998; Durrer et al., 1995), and there is
evidence supporting the importance of this localization
for type I IFN gene induction (Lund et al., 2003). Although
the mechanisms that determine endosomal trafficking
of CpG-A or virus in pDCs remain unknown, one may
envisage a molecule(s) that is selectively expressed in
endosomes of pDCs and assists the endosomal reten-
tion of ligands.
MyD88 Signaling Pathway for IRF1 Activation
As mentioned above, IRF1 is not essential for the cyto-
solic IFN induction pathway. However, IRF1 participates
in type I IFN gene induction in some facets of TLR signal-
ing. Similarly to IRF7, IRF1 directly interacts with MyD88
(Negishi et al., 2006). IRF1 interacts with the middle re-
gion (the intermediary domain and part of the TIR do-main) of MyD88 and is activated in a MyD88-dependent
manner (Figure 3D). The critical function of IRF1 in
MyD88 signaling is underscored by the observation
that the induction of a certain set of genes, such as those
that encode IFN-b, inducible nitric-oxide synthase
(iNOS), and IL-12p35, by CpG-B is severely impaired in
bone marrow-derived myeloid DCs cultured with granu-
locyte macrophage colony-stimulating factor (GM-CSF)
from Irf12/2 mice (Negishi et al., 2006). In contrast,
Irf12/2 pDCs exhibit normal IFN-a and IFN-b gene induc-
tion upon CpG-A stimulation, indicating the cell type-
and/or ligand-specific involvement of IRF1 in the
MyD88-dependent signaling pathway. As opposed to
IRF7, which is induced by type I IFN, IRF1 is strongly in-
duced by IFN-g signaling. Indeed, IFN-b gene induction
by CpG-B is strongly enhanced by the pretreatment of
DCs with IFN-g, and this enhancement is dependent on
IRF1. Thus, the IRF1 induced by IFN-g binds to MyD88
and is modified by unidentified signaling molecule(s) to
migrate into the nucleus and activate gene induction
(Figure 3D). It is likely that IRF1 is phosphorylated in
the MyD88 complex; however, the upstream mediators
of the IRF1 pathway await identification.
Notably, Myd882/2 as well as Irf12/2 mice are com-
monly susceptible to several pathogens, including
Listeriamonocytogenes, Toxoplasma gondii, andMyco-
bacterium tuberculosis (Lohoff and Mak, 2005). To elim-
inate these pathogens, IFN-g produced by T cells and
other cells is required for the enhancement of signaling
in macrophages and DCs for an efficient induction of
inflammatory mediators such as IFN-b and iNOS, which
may be mediated by the MyD88-dependent activation
of IRF1.
Evolutionary Implications
Both type I IFN and IRF genes are found in vertebrates
but not in invertebrates and are involved mainly in the
host defense against pathogens and stresses. In con-
trast, the JAK-STAT pathway, which is known to be
functional even in insects, participates in several other
nonimmunological systems including embryonic devel-
opment (Leonard and O’Shea, 1998). Thus, the IRF fam-
ily and its functions (including the type I IFN gene induc-
tion) have evolved, perhaps later than the JAK-STAT
family. Recent studies have suggested that viral infec-
tion in invertebrates triggers an RNA silencing-based an-
tiviral response (i.e., RNA interference: RNAi) instead of
IFN induction; however, such a response is conceivably
insufficient to eradicate viruses. Indeed, it has been
shown that in invertebrate cells such as Drosophila me-
lanogaster cells, in which there is no IRF or IFN, viruses
such as VSV replicate without any apparent cytopatho-
genic effects, usually resulting in the establishment of
persistent infection. Therefore, vertebrates might have
evolved an IRF-IFN system to enable the mounting of
efficient immune responses to viruses. In this regard, it
is noteworthy that the IRF-IFN system was evolved at
a similar time when the adaptive immune system was
evolved. Indeed, type I IFN plays an essential role in
linking the innate and adaptive response against viral
infections (van den Broek et al., 1995; see also the ac-
companying review Stetson and Medzhitov, 2006b).
It is also interesting that IFN-a and -b genes are con-
stitutively expressed in normally growing cells, which
Review
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This constitutive expression is low but biologically im-
portant, providing a foundation for boosting the signal-
ing of other cytokines such as IFN-g and IL-6 (Taniguchi
and Takaoka, 2001). Furthermore, IFN-b gene is induced
by several nonviral agents such as the receptor activator
of NF-kB ligand (RANKL), which activates NF-kB, c-JUN,
and c-Fos, but not IRFs (Takayanagi et al., 2002). The
RANKL-mediated IFN-b gene induction occurs very
weakly, but is essential for the regulation of osteoclast
differentiation. Thus, from an evolutionary perspective,
IRFs might have evolved to enhance the type I IFN
gene induction against viral infections. We also infer
that two structurally related IRF3 and IRF7 genes may
have evolved from a common ancestor, wherein IRF7
gene became under the control of IFN signaling for
further amplification of the IFN response against viral
infections.
In addition to IRF system, multiple IFN-a genes them-
selves may have also evolved to enhance the IFN-medi-
ated antiviral immune response. IFN-aand -bgenes have
diverged from a common ancestor (Taniguchi et al.,
1980), but IFN-b seems to be the primordial IFN gene
from which IFN-agenes haveevolved to form a multigene
subfamily. Indeed, the induction of most IFN-a genes is
dependent on IFN-b signaling and IFN-b-induced IRF7.
The evolution of these positive-feedback mechanisms
must have been beneficial or even essential for the anti-
viral immunity of the host.
Future Perspective
There is accumulating evidence for multiple signaling
pathways for type I IFN induction. Recent progress has
been particularly made in the identification of receptors,
signal transduction molecules, and transcription factors
that are required for the induction of type I IFN genes
against cytosolic RNA virus infections, as well as for
the robust type I IFN gene induction in pDCs. In addition
to these signaling pathways, the list of newly identified
type I IFN induction pathways is rapidly growing and
will continue to grow. A striking example is the recently
identified pathway for the activation of IRF3 by cytosolic
dsDNA (Ishii et al., 2006; Stetson and Medzhitov, 2006a).
The analysis of receptor systems and downstream signal
transduction molecules required for responses to cyto-
solic dsDNA is an exciting area for future research. Fur-
thermore, in contrast to the HSV-mediated type I IFN
gene-induction pathway in pDCs, which has been exten-
sively studied recently and known to be TLR9-MyD88-
IRF7 dependent, much less is known about the pathway
activated by HSV in other cell types. In fibroblasts and
conventional DCs, HSV infection activates the IRF3-
and IRF7-dependent, but TLR-independent, type I IFN
induction pathway (Honda et al., 2005b); however, the
receptors, adaptors, and kinases involved all remain un-
known. The replication of HSV occurs entirely in the nu-
cleus, which is distinct from that of most RNA viruses,
whose entire life cycle occur in the cytoplasm. Therefore,
the activation of type I IFN responses by HSV might be
mediated by a nuclear surveillance system that detects
viral infections, and one can envisage a receptor that
senses nuclear viral DNAs.
Immune systems utilize properly the IRF-IFN system
to induce diverse responses. Besides the beneficialaspects of the type I IFN system on the host defense
against viral infection, accumulating evidence also sug-
gests that an aberrant activation of immune systems by
high amounts of type I IFN production contributes to the
development of autoimmune diseases, such as sys-
temic lupus erythematosus (SLE) (see the accompany-
ing review by Banchereau and Pascual, 2006). SLE
patients are characterized by the production of autoan-
tibodies to certain cellular macromolecules, particularly
against self-nucleic acids, such as small nuclear RNA
with proteins (snRNPs) as well as chromatin. These au-
toantibodies to nucleic acids form immune complexes
that can be taken up into endosomes of pDCs or other
cells through the Fc receptor and efficiently stimulate
TLR7, TLR8, or TLR9 to produce type I IFNs. Thus,
self-RNA and -DNA are potentially immunogenic, and
an aberrant activation of the TLR7-, TLR8-, or TLR9-me-
diated MyD88-IRF7 and/or MyD88-IRF1 activation path-
ways for type I IFN induction might be responsible for
the pathogenesis of autoimmune diseases.
A more detailed understanding of how signaling path-
ways turn on, as well as turn off, the IRF system is impor-
tant for the development of new therapeutic interven-
tions for infectious and autoimmune diseases. It should
also be noted that IRFs have roles in other aspects of
host defense, such as the regulation of oncogenesis,
and the study of these roles is emerging as an interesting
area of research.
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